Renal Cell Carcinoma

P2, N=36, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=75, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended

P2, N=10, Terminated, Jinling Hospital, China | N=100 --> 10 | Trial completion date: Dec 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Oct 2025; The patient enrollment rate is proceeding too slowly

Cell experiments revealed that interference of UBE2Q1-AS1 significantly inhibited the proliferation and migration of 786-O cells. The migrasome-associated lncRNA model accurately predicts ccRCC patient prognosis, offering new insights for immunotherapy and clinical applications.

Radiology plays a central role in the management of these therapies, as phenomena such as pseudoprogression challenge the classic RECIST (response evaluation criteria in solid tumors) system, and early detection of immune-mediated side effects often precedes clinical manifestation in imaging. The growing complexity of therapy requires radiologists to possess precise image interpretation, interdisciplinary collaboration, and knowledge of immunological principles, thus, enabling an improved prognosis for many tumor types.

It underscores the necessity of genetic testing for MPC patients and demonstrates that aggressive management of primary tumors can improve the patient's quality of life. This case provides valuable insights for clinical research and treatment strategies for MPC.

Additionally, we found eccDNA carrying full protein-coding genes that are overexpressed in transcriptional analyses. Our findings suggest that small eccDNAs with miRNA genes are functional and contribute to the tumorigenesis of renal cell carcinoma.

SLC44A4 gene could be a biomarker to predict the prognosis of CRC patients. In addition, this new prognostic model that we proposed can improve the predictive ability to evaluate the prognosis and clinical outcomes of CRC patients.

This case highlights the potential for misdiagnosis or delayed diagnosis of BHD syndrome in patients presenting with spontaneous pneumothorax. A detailed family history, early recognition, and multidisciplinary evaluation are essential for early and appropriate management.

The first-in-class GPR65 inhibitor, PTT-4256, is now under evaluation in the Phase I/II RAISIC-1 trial (NCT06634849) in solid tumours, including RCC. Targeting acid-sensing pathways represents a novel and promising therapeutic strategy in RCC, aiming to remodel the TME and overcome ICI resistance. Integrating GPR65 inhibition with existing immunotherapies may define the next era of RCC management, warranting continued translational and clinical investigation.

PRNRP represents a distinct KRAS-mutant RCC subtype with unique metabolic and genomic features linked to its distal nephron origin. This contrasts with the genomic complexity and aggressive clinical behavior observed in KRAS-mutant PRCC and URCC, highlighting the need for subtype-specific diagnostic criteria and therapeutic strategies.

Differential considerations, including epithelioid sarcoma, poorly differentiated chordoma, CRINET, choroid plexus carcinoma, and rare composite tumors, further complicate the diagnostic landscape. A comprehensive, multimodal diagnostic approach combining histologic, immunophenotypic, and molecular data is essential to accurately identify AT/RT and guide clinical management, particularly in diagnostically ambiguous or atypical cases.